<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35953502</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">93</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-022-00517-6</ELocationID><Abstract><AbstractText>The Pfizer COVID-19 vaccine is associated with increased myocarditis incidence. Constantly evolving evidence regarding incidence and case fatality of COVID-19 and myocarditis related to infection or vaccination, creates challenges for risk-benefit analysis of vaccination. Challenges are complicated further by emerging evidence of waning vaccine effectiveness, and variable effectiveness against variants. Here, we build on previous work on the COVID-19 Risk Calculator (CoRiCal) by integrating Australian and international data to inform a Bayesian network that calculates probabilities of outcomes for the delta variant under different scenarios of Pfizer COVID-19 vaccine coverage, age groups (&#x2265;12 years), sex, community transmission intensity and vaccine effectiveness. The model estimates that in a population where 5% were unvaccinated, 5% had one dose, 60% had two doses and 30% had three doses, there was a substantially greater probability of developing (239-5847 times) and dying (1430-384,684 times) from COVID-19-related than vaccine-associated myocarditis (depending on age and sex). For one million people with this vaccine coverage, where transmission intensity was equivalent to 10% chance of infection over 2 months, 68,813 symptomatic COVID-19 cases and 981 deaths would be prevented, with 42 and 16 expected cases of vaccine-associated myocarditis in males and females, respectively. These results justify vaccination in all age groups as vaccine-associated myocarditis is generally mild in the young, and there is unequivocal evidence for reduced mortality from COVID-19 in older individuals. The model may be updated to include emerging best evidence, data pertinent to different countries or vaccines and other outcomes such as long COVID.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-9178-3869</Identifier><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayfield</LastName><ForeName>Helen J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Short</LastName><ForeName>Kirsty R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Samuel J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-7542-8664</Identifier><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puranik</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengersen</LastName><ForeName>Kerrie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Litt</LastName><ForeName>John C B</ForeName><Initials>JCB</Initials><Identifier Source="ORCID">0000-0002-3103-0064</Identifier><AffiliationInfo><Affiliation>Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Advisory Committee, Immunisation Coalition, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lau</LastName><ForeName>Colleen L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-8288-4169</Identifier><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. colleen.lau@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1193826</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant><Grant><GrantID>2007919</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. K.R.S. is a consultant for Sanofi, Roche and NovoNordisk. The opinions and data presented in this manuscript are of the authors and are independent of these relationships.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35953502</ArticleId><ArticleId IdType="pmc">PMC9371378</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00517-6</ArticleId><ArticleId IdType="pii">10.1038/s41541-022-00517-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swiss Agency for Therapeutic Products. Swissmedic Grants Authorisation for the first COVID-19 vaccine in Switzerland [accessed 22 January 2022], https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html (2020).</Citation></Reference><Reference><Citation>BioSpace. Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-profit Price for Donation to Poorest Countries [accessed 22 January 2022], https://www.biospace.com/article/releases/pfizer-and-biontech-expand-collaboration-with-u-s-to-provide-500-million-additional-covid-19-vaccine-doses-at-not-for-profit-price-for-donation-to-poorest-countries/ (2021).</Citation></Reference><Reference><Citation>COVID19 Vaccine Tracker. Pfizer/BioNTech: Comirnaty [accessed 22 January 2022], https://covid19.trackvaccines.org/vaccines/6/ (2022).</Citation></Reference><Reference><Citation>Heller, J. Israel Sees Probable Link between Pfizer Vaccine and Myocarditis Cases (Reuters, 2021), https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines among Adolescents and Young Adults [accessed 22 January 2022], https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html (2021).</Citation></Reference><Reference><Citation>Wu, K. J. Doctors Are Puzzled by Heart Inflammation in the Young and Vaccinated. (The Atlantic, 2021). https://www.theatlantic.com/health/archive/2021/07/vaccination-myocarditis-kids/619339/.</Citation></Reference><Reference><Citation>Melbourne Institute. Vaccine Hesitancy Tracker [accessed 22 January 2022], https://melbourneinstitute.unimelb.edu.au/publications/research-insights/ttpn/vaccination-report (2021).</Citation></Reference><Reference><Citation>Australian Government Department of Health. Who Can Get Vaccinated [accessed 22 January 2022], https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/who-can-get-vaccinated#access-to-comirnaty-pfizer (2022).</Citation></Reference><Reference><Citation>Wong MCS, et al. Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine. 2021;39:1148&#x2013;1156. doi: 10.1016/j.vaccine.2020.12.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.12.083</ArticleId><ArticleId IdType="pmc">PMC7832076</ArticleId><ArticleId IdType="pubmed">33461834</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger P, Peretti-Watel P. Understanding the determinants of acceptance of COVID-19 vaccines: a challenge in a fast-moving situation. Lanc. Publ. Heal. 2021;6:e195&#x2013;e196. doi: 10.1016/S2468-2667(21)00029-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00029-3</ArticleId><ArticleId IdType="pmc">PMC7864794</ArticleId><ArticleId IdType="pubmed">33556329</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Technical Advisory Group on Immunisation. Weighing up the potential benefits and risk of harm from COVID-19 vaccine AstraZeneca [accessed December 2021], https://www.health.gov.au/sites/default/files/documents/2021/06/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca_2.pdf (2021).</Citation></Reference><Reference><Citation>Australian Government Department of Health. Guidance on Myocarditis and Pericarditis after mRNA COVID-19 Vaccines [accessed January 2022], https://www.health.gov.au/sites/default/files/documents/2021/10/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines.pdf (2021).</Citation></Reference><Reference><Citation>Australian Government Department of Health. COVID-19 Vaccination&#x2013;Vaccination Data&#x2013;1 October 2021 [accessed January 2022], https://www.health.gov.au/resources/publications/covid-19-vaccination-vaccination-data-1-october-2021 (2021).</Citation></Reference><Reference><Citation>Australian Government Department of Health. ATAGI Statement on Revised Recommendations on the Use of COVID-10 Vaccine AstraZeneca, 17 June 2021 [accessed January 2022], https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021 (2021).</Citation></Reference><Reference><Citation>Tartof SY, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2011;398:1407&#x2013;1416. doi: 10.1016/S0140-6736(21)02183-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02183-8</ArticleId><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIntyre CR, Veness B, Berger D, Hamad N, Bari N. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination&#x2014;a risk-benefit analysis for people &lt;60 years in Australia. Vaccine. 2021;39:4784&#x2013;4787. doi: 10.1016/j.vaccine.2021.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.013</ArticleId><ArticleId IdType="pmc">PMC8270740</ArticleId><ArticleId IdType="pubmed">34272095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau CL, et al. Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine. 2021;39:7429&#x2013;7440. doi: 10.1016/j.vaccine.2021.10.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.10.079</ArticleId><ArticleId IdType="pmc">PMC8566665</ArticleId><ArticleId IdType="pubmed">34810000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayfield HJ, et al. Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine. Vaccine. 2022 doi: 10.1016/j.vaccine.2022.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC8989774</ArticleId><ArticleId IdType="pubmed">35450781</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunisation Coalition. CoRiCal: Covid Risk Calculator [accessed January 2022], https://corical.immunisationcoalition.org.au (2021).</Citation></Reference><Reference><Citation>Chodick, G. et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Network Open 2021. 10.1001/jamanetworkopen.2021.15985 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185600</ArticleId><ArticleId IdType="pubmed">34097044</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez, J. L. Efficacy and Safety of BNT162b2 Booster&#x2013;C4591031 2 Month Interim Analysis [accessed December 2021], https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf (2021).</Citation></Reference><Reference><Citation>Nasreen S, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7:379&#x2013;385. doi: 10.1038/s41564-021-01053-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01053-0</ArticleId><ArticleId IdType="pubmed">35132198</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N. Engl. J. Med. 2022;386:340&#x2013;350. doi: 10.1056/NEJMoa2115481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115481</ArticleId><ArticleId IdType="pmc">PMC8781262</ArticleId><ArticleId IdType="pubmed">35021002</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Government Department of Health. Coronavirus (COVID-19) Case Numbers and Statistics&#x2014;cases and Deaths by Age and Sex [accessed December 2021], https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics (2021).</Citation></Reference><Reference><Citation>Australian Government Department of Health. Coronavirus Disease 2019 (COVID-19) Epidemiology Reports, Australia, 2020&#x2013;2021 [accessed Dec 2021], https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel_coronavirus_2019_ncov_weekly_epidemiology_reports_australia_2020.htm (2021).</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. National, State and Territory population [accessed December 2021], https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do001_202103.xls (2021).</Citation></Reference><Reference><Citation>Li X, et al. Characterising the background incidence rates of adverse events of special interest COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021 doi: 10.1101/2021.03.25.21254315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.25.21254315</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N. Engl. J. Med. 2021;385:1078&#x2013;1090. doi: 10.1056/NEJMoa2110475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, J. R. Myopericarditis following COVID-19 vaccination: updates from the Vaccine Adverse Event Reporting System (VAERS) [accessed January 2022], https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/03-COVID-Su-508.pdf (2021).</Citation></Reference><Reference><Citation>Kyt&#xf6; V, Saraste A, Voipio-Pulkki L, Saukko P. Incidence of fatal myocarditis: a population-based study in Finland. Am. J. Epidemiol. 2007;165:570&#x2013;574. doi: 10.1093/aje/kwk076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwk076</ArticleId><ArticleId IdType="pubmed">17237135</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutic Goods Administration. COVID-19 vaccine weekly safety report&#x2014;09-12-2021 [accessed December 2021], https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-09-12-2021 (2021).</Citation></Reference><Reference><Citation>Vaccines and Related Biological Products Advisory Committee. October 14&#x2013;15, 2021 Meeting Presentation [accessed December 2021], https://www.fda.gov/media/153086/download (2021).</Citation></Reference><Reference><Citation>Oster M, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327:331&#x2013;340. doi: 10.1001/jama.2021.24110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley BJR, et al. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur. J. Clin. Investig. 2021;51:e13669. doi: 10.1111/eci.13679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13679</ArticleId><ArticleId IdType="pmc">PMC8646627</ArticleId><ArticleId IdType="pubmed">34516657</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Government Department of Health. COVID-19 Vaccination&#x2013;Vaccination data&#x2014;3 January 2022 [accessed January 2022], https://www.health.gov.au/resources/publications/covid-19-vaccination-vaccination-data-3-january-2022 (2022).</Citation></Reference><Reference><Citation>Therapeutic Goods Administration. COVID-19 Vaccine Weekly Safety Report [accessed December 2021], https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report (2021).</Citation></Reference><Reference><Citation>Sadarangani M, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. 2021;39:2020&#x2013;2023. doi: 10.1016/j.vaccine.2021.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.020</ArticleId><ArticleId IdType="pmc">PMC7938751</ArticleId><ArticleId IdType="pubmed">33736921</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadi, N. et al. Models of COVID-19 vaccine prioritization: a systematic literature search and narrative review. BMC Med. 19, 10.1186/s12916-021-02190-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632563</ArticleId><ArticleId IdType="pubmed">34847950</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas SM, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin. Infect. Dis. 2021;73:2257&#x2013;2264. doi: 10.1093/cid/ciab079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab079</ArticleId><ArticleId IdType="pmc">PMC7929033</ArticleId><ArticleId IdType="pubmed">33515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery J, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021;6:1202&#x2013;1206. doi: 10.1001/jamacardio.2021.2833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.2833</ArticleId><ArticleId IdType="pmc">PMC8243257</ArticleId><ArticleId IdType="pubmed">34185045</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. Coronavirus Vaccine&#x2013;Weekly Summary of Yellow Card Reporting [accessed January 2022], https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (2022).</Citation></Reference><Reference><Citation>Mevorach D, et al. Myocarditis after BNT162b2 vaccine against COVID-19 in Israel. N. Engl. J. Med. 2021;385:2140&#x2013;2149. doi: 10.1056/NEJMoa2109730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109730</ArticleId><ArticleId IdType="pmc">PMC8531987</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton, N. &amp; Neil, M. Risk assessment and decision analysis with Bayesian networks. 2nd edn (CRC Press, 2019).</Citation></Reference><Reference><Citation>Marcot BG. Common quandaries and their practical solutions in Bayesian network modeling. Ecol. Model. 2017;358:1&#x2013;9. doi: 10.1016/j.ecolmodel.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecolmodel.2017.05.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Zhai, X. &amp; Luo, Q. How COVID-19 impacts Chinese travelers&#x2019; mobility decision-making processes: a Bayesian network model. Information and Communication Technologies in Tourism. 557&#x2013;563. 10.1007/978-3-030-65785-7_53 (2021).</Citation></Reference><Reference><Citation>Fenton, N. E. et al. A Bayesian network model for personalized COVID-19 risk assessment and contact tracing. Preprint at 10.1101/2020.07.15.20154286v2 (2021).</Citation></Reference><Reference><Citation>Prodhan, G. &amp; Fenton, N. Extending the range of COVID-19 risk factors in a Bayesian network model for personalized risk assessment. Preprint at 10.1101/2020.10.20.20215814v1 (2020).</Citation></Reference><Reference><Citation>Lai. K. &amp; Yanushkevich, S. N. Machine reasoning to assess pandemics risks: case of USS Theodore Roosevelt. Preprint at https://arxiv.org/abs/2008.11040 (2020).</Citation></Reference><Reference><Citation>Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: aetiology, diagnosis and management. Clin. Med. J. 2021 doi: 10.7861/clinmed.2021-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0121</ArticleId><ArticleId IdType="pmc">PMC8439515</ArticleId><ArticleId IdType="pubmed">34507935</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory Y, et al. Sudden unexpected death in persons &lt;40 years of age. Am. J. Cardiol. 1991;68:1388&#x2013;1392. doi: 10.1016/0002-9149(91)90251-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(91)90251-F</ArticleId><ArticleId IdType="pubmed">1951130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis &#x2013; diagnosis, treatment option, and current controversies. Nat. Rev. Cardiol. 2015;12:670&#x2013;680. doi: 10.1038/nrcardio.2015.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.108</ArticleId><ArticleId IdType="pubmed">26194549</ArticleId></ArticleIdList></Reference><Reference><Citation>Luetkens JA, et al. Feature-tracking myocardial strain analysis in acute myocarditis: diagnostic value and association with myocardial oedema. Eur. Radio. 2017;27:4661&#x2013;4671. doi: 10.1007/s00330-017-4854-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-017-4854-4</ArticleId><ArticleId IdType="pubmed">28500369</ArticleId></ArticleIdList></Reference><Reference><Citation>Luetkens JS, et al. Comprehensive cardiac magnetic resonance for short-term follow-up in acute myocarditis. J. Am. Heart Assoc. 2016 doi: 10.1161/JAHA.116.003603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.003603</ArticleId><ArticleId IdType="pmc">PMC5015395</ArticleId><ArticleId IdType="pubmed">27436306</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich MG, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White paper. J. Am. Coll. Cardiol. 2009;53:1475&#x2013;1487. doi: 10.1016/j.jacc.2009.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.02.007</ArticleId><ArticleId IdType="pmc">PMC2743893</ArticleId><ArticleId IdType="pubmed">19389557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira VM, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J. Am. Coll. Cardiol. 2018;72:3158&#x2013;3176. doi: 10.1016/j.jacc.2018.09.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.09.072</ArticleId><ArticleId IdType="pubmed">30545455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>